Table 1.
Baseline characteristics.
| Variable | Overall (n = 11,418) |
HBR Group (n = 502) | No-HBR Group (n = 916) | p-Value a |
|---|---|---|---|---|
| Age, year | 66.2 ± 24.3 | 73.2 ± 9.3 | 62.3 ± 9.5 | <0.001 |
| Age ≥ years | 346 (24.4) | 271 (54.0) | 75 (8.2) | <0.001 |
| Female gender | 395 (27.9) | 197 (39.2) | 198 (21.6) | <0.001 |
| BMI, kg/m2 | 24.3 ± 3.2 | 23.3 ± 3.2 | 24.8 ± 3.0 | <0.001 |
| Diabetes mellitus | 613 (43.2) | 274 (54.6) | 339 (37.0) | <0.001 |
| Hypertension | 916 (64.6) | 378 (75.3) | 538 (58.7) | <0.001 |
| Dyslipidemia | 659 (46.5) | 233 (46.6) | 462 (50.4) | 0.141 |
| Current smoking | 368 (26.0) | 67 (13.3) | 301 (32.9) | <0.001 |
| Diagnosis | <0.001 | |||
| Angina | 855 (60.3) | 261 (52.0) | 594 (64.8) | |
| NSTEMI | 449 (31.7) | 211 (42.0) | 238 (26.0) | |
| STEMI | 114 (8.0) | 30 (6.0) | 84 (9.2) | |
| Previous myocardial infarction | 354 (25.0) | 139 (27.7) | 215 (23.5) | 0.100 |
| Previous hemorrhagic stroke | 17 (1.2) | 17 (1.3) | 0 (0) | <0.001 |
| Previous ischemic stroke | 131 (9.2) | 94 (18.7) | 37 (4.0) | <0.001 |
| Previous antiplatelet therapy | 554 (50.5) | 213 (57.1) | 341 (47.0) | 0.002 |
| Previous oral anticoagulation | 8 (0.6) | 8 (1.6) | 0 (0) | <0.001 |
| Moderate CKD (eGFR 30–59) | 246 (17.3) | 198 (39.4) | 48 (5.2) | <0.001 |
| Severe CKD (eGFR < 30) | 85 (6.0) | 85 (16.9) | 0 (0) | <0.001 |
| Mild anemia (Hb 11–12.9 g/dL for male, 11–11.9 g/dL for female) | 346 (24.4) | 178 (35.5) | 168 (18.3) | <0.001 |
| Severe anemia (Hb < 11 g/dL) | 236 (16.6) | 236 (47.0) | 0 (0) | <0.001 |
| Platelet < 100 × 109/L | 22 (1.6) | 22 (4.4) | 0 (0) | <0.001 |
| Liver cirrhosis | 27 (1.9) | 27 (5.4) | 0 (0) | <0.001 |
| Malignancy | 19 (1.3) | 19 (3.8) | 0 (0) | <0.001 |
| Medication | <0.001 | |||
| Clopidogrel | 1208 (85.2) | 453 (90.2) | 755 (82.4) | |
| New P2Y12 inhibitor | 180 (12.7) | 38 (7.6) | 142 (15.5) |
Values are n (%) or mean ± standard deviation. a Between HBR and no-HBR group. BMI, body mass index; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; Hb, hemoglobin; HBR, high bleeding risk; NSTEMI, non-ST elevation myocardial infarction; STEMI, ST elevation myocardial infarction.